CD274 and non-small cell lung carcinoma: Antibodies targeting programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) are now approved for treating multiple cancers, including non-small-cell lung cancer (NSCLC) (Borghaei et al., 2015, Reck et al., 2016).